{"transactions":[{"id":2086445,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Warrant (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrant is immediately exercisable in full."}],"balance_after":18094,"derivative":{"exercise_price":6.9,"expiration_date":"2027-12-12","underlying":"Common Stock","underlying_shares":18094},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086444,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in 3 equal annual installments commencing on January 28, 2023."}],"balance_after":29781,"derivative":{"exercise_price":16.36,"expiration_date":"2032-01-28","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086443,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":29781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in 3 equal annual installments commencing on February 8, 2022."}],"balance_after":29781,"derivative":{"exercise_price":16.36,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":29781},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086442,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020."}],"balance_after":39708,"derivative":{"exercise_price":11.58,"expiration_date":"2029-04-02","underlying":"Common Stock","underlying_shares":39708},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086441,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":59563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017."}],"balance_after":59563,"derivative":{"exercise_price":5.03,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":59563},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086440,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":39709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016."}],"balance_after":39709,"derivative":{"exercise_price":5.03,"expiration_date":"2025-06-09","underlying":"Common Stock","underlying_shares":39709},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086439,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (right to buy)","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":19854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015."}],"balance_after":19854,"derivative":{"exercise_price":5.03,"expiration_date":"2024-04-11","underlying":"Common Stock","underlying_shares":19854},"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}},{"id":2086438,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":121627,"kind":"person","name":"LaBella Nicholas A. Jr.","position":1,"cik":"0001487698","reported_name":"LaBella Nicholas A. Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-14T19:31:17.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":18094,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation (\"Larkspur\") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the \"Business Combination Agreement\") by and among ZyVersa Therapeutics, Inc., a Florida corporation (\"Old ZyVersa\"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur (\"Merger Sub\") pursuant to which Merger Sub merged with and into Old ZyVersa (the \"Acquisition Merger\"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer."}],"balance_after":18094,"source":{"system":"sec-edgar","filing":"0001493152-22-035483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487698/000149315222035483/ownership.xml","form_type":"4"}}]}